Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

Hepatitis C treatment benefit extends to nonhepatic cancers

13 Oct 2020

Treatment for hepatitis C virus (HCV) infection confers an added benefit of reducing the incidence of nonhepatic cancers, a study suggests.

The study drew data from the MarketScan Databases and included 62,078 patients with newly diagnosed HCV infection. Of the patients, 17,302 (28 percent) initiated HCV treatment, with 15,322 of them completing 8–16 weeks of therapy (minimally effective).

Multivariable, time‐varying Cox proportional hazards models showed that compared with untreated patients, those who initiated HCV treatment had an 11-percent lower risk of developing a nonhepatic cancer (hazard ratio [HR], 0.89, 95 percent confidence interval [Cl], 0.82–0.96).

The risk reduction was slightly higher when patients completed a minimally effective treatment (HR, 0.87, 95 percent Cl, 0.80–0.95). This was seen across subgroups defined by sex, age, and presence of cirrhosis or diabetes.

When analysis was stratified according to cancer or therapy subtypes, the association between HCV treatment and nonhepatic cancers was consistent for pancreatic and lung cancers and dual HCV therapy.

Overall, the findings suggest that treating HCV infection has the potential to reduce the burden of extrahepatic cancer associated with chronic HCV infection, according to the researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 5 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.